Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects.

Sidharta PN, van Giersbergen PLM, Dingemanse J.

Pharmacology. 2018;102(5-6):339-346. doi: 10.1159/000492936. Epub 2018 Nov 1.

PMID:
30384375
2.

Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study.

Gueret P, Combe S, Krezel C, Fuseau E, van Giersbergen PL, Petitou M, Neuhart E.

Eur J Clin Pharmacol. 2017 Jan;73(1):15-28. doi: 10.1007/s00228-016-2143-9. Epub 2016 Oct 15.

PMID:
27742998
3.

First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action.

Gueret P, Combe S, Krezel C, Fuseau E, van Giersbergen PL, Petitou M, Neuhart E.

Eur J Clin Pharmacol. 2016 Sep;72(9):1041-50. doi: 10.1007/s00228-016-2077-2. Epub 2016 Jun 3.

PMID:
27259709
4.

Comorbidities and pharmacotherapies in patients with Gaucher disease type 1: The potential for drug-drug interactions.

Utz J, Whitley CB, van Giersbergen PL, Kolb SA.

Mol Genet Metab. 2016 Feb;117(2):172-8. doi: 10.1016/j.ymgme.2015.12.001. Epub 2015 Dec 2. Review.

5.

Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.

Sidharta PN, van Giersbergen PL, Wolzt M, Dingemanse J.

Br J Clin Pharmacol. 2014 Nov;78(5):1035-42. doi: 10.1111/bcp.12447.

6.

EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs.

Gueret P, Krezel C, Fuseau E, van Giersbergen PL, Petitou M, Neuhart E.

J Thromb Haemost. 2014 Jan;12(1):24-33. doi: 10.1111/jth.12453.

7.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.

Sidharta PN, van Giersbergen PL, Dingemanse J.

J Clin Pharmacol. 2013 Nov;53(11):1131-8. doi: 10.1002/jcph.152. Epub 2013 Sep 4.

PMID:
23900878
8.

First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.

Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, Arbe-Barnes S, Charman SA, Gutierrez M, Wittlin S, Vennerstrom JL.

Br J Clin Pharmacol. 2013 Feb;75(2):524-37. doi: 10.1111/j.1365-2125.2012.04368.x.

9.

Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.

Lebrec D, Bosch J, Jalan R, Dudley FJ, Jessic R, Moreau R, Garcia-Pagan JC, Mookerjee RP, Chiossi E, Van Giersbergen PL, Kusic-Pajic A, Dingemanse J.

Eur J Clin Pharmacol. 2012 May;68(5):533-41. doi: 10.1007/s00228-011-1157-6. Epub 2011 Nov 20.

PMID:
22101624
10.

Macitentan: entry-into-humans study with a new endothelin receptor antagonist.

Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J.

Eur J Clin Pharmacol. 2011 Oct;67(10):977-84. doi: 10.1007/s00228-011-1043-2. Epub 2011 May 4.

11.

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.

Dingemanse J, van Giersbergen PL, Patat A, Nilsson PN.

Antivir Ther. 2010;15(2):157-63. doi: 10.3851/IMP1506.

PMID:
20386070
12.

Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects.

Sidharta PN, van Giersbergen PL, Dingemanse J.

J Clin Pharmacol. 2009 Oct;49(10):1168-75. doi: 10.1177/0091270009341181. Epub 2009 Jul 22.

PMID:
19625629
13.

Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis.

Maegawa GH, van Giersbergen PL, Yang S, Banwell B, Morgan CP, Dingemanse J, Tifft CJ, Clarke JT.

Mol Genet Metab. 2009 Aug;97(4):284-91. doi: 10.1016/j.ymgme.2009.04.013. Epub 2009 May 3.

PMID:
19447653
14.

Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan.

Dingemanse J, Halabi A, van Giersbergen PL.

J Clin Pharmacol. 2009 Apr;49(4):455-64. doi: 10.1177/0091270008330157.

PMID:
19318695
15.

In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans.

van Giersbergen PL, Treiber A, Dingemanse J.

Int J Clin Pharmacol Ther. 2009 Mar;47(3):169-77.

PMID:
19281726
16.

Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion.

van Giersbergen PL, Dingemanse J.

Clin Drug Investig. 2007;27(11):797-802.

PMID:
17914898
17.

Influence of ethnic origin and sex on the pharmacokinetics of clazosentan.

van Giersbergen PL, Gunawardena KA, Dingemanse J.

J Clin Pharmacol. 2007 Nov;47(11):1374-80. Epub 2007 Sep 28.

PMID:
17906281
18.

Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase.

van Giersbergen PL, Dingemanse J.

J Clin Pharmacol. 2007 Oct;47(10):1277-82. Epub 2007 Aug 24.

PMID:
17720777
19.

Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.

van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J.

Clin Pharmacol Ther. 2007 Mar;81(3):414-9. Epub 2007 Jan 24. Erratum in: Clin Pharmacol Ther. 2007 Mar;81(3):460.

PMID:
17251982
20.

Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.

van Giersbergen PL, Dingemanse J.

Eur J Clin Pharmacol. 2007 Feb;63(2):151-8. Epub 2006 Apr 25.

PMID:
16636870
21.

Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol.

van Giersbergen PL, Halabi A, Dingemanse J.

Int J Clin Pharmacol Ther. 2006 Mar;44(3):113-8.

PMID:
16550733
22.

Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects.

Dingemanse J, Gunawardena KA, van Giersbergen PL.

Br J Clin Pharmacol. 2006 Apr;61(4):405-13.

23.

Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects.

van Giersbergen PL, Dingemanse J.

J Clin Pharmacol. 2005 Jan;45(1):42-7.

PMID:
15601804
24.

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.

Dingemanse J, van Giersbergen PL.

Clin Pharmacokinet. 2004;43(15):1089-115. Review.

PMID:
15568889
25.

Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.

Liefeldt L, van Giersbergen PL, Dingemanse J, Rudolph B, Walde T, Budde K, Neumayer HH, Hocher B.

Am J Kidney Dis. 2004 May;43(5):923-6.

PMID:
15112184
26.
27.

Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjects.

Van Giersbergen PL, Dingemanse J.

Eur J Drug Metab Pharmacokinet. 2003 Jan-Mar;28(1):49-54.

PMID:
14503664
28.

Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry.

van Giersbergen PL, Wipfli P, Dingemanse J.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 25;792(2):369-73.

PMID:
12860045
29.

Effect of severe renal impairment on the pharmacokinetics and tolerability of the parenteral endothelin antagonist tezosentan.

van Giersbergen PL, Dingemanse J.

Int J Clin Pharmacol Ther. 2003 Jun;41(6):261-6.

PMID:
12816178
30.

In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans.

Treiber A, Van Giersbergen PL, Dingemanse J.

Xenobiotica. 2003 Apr;33(4):399-414.

PMID:
12745875
31.

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.

Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, van Giersbergen PL.

Clin Pharmacol Ther. 2003 Apr;73(4):372-82.

PMID:
12709727
32.

Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.

Dingemanse J, Schaarschmidt D, van Giersbergen PL.

Clin Pharmacokinet. 2003;42(3):293-301.

PMID:
12603176
33.

Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.

van Giersbergen PL, Popescu G, Bodin F, Dingemanse J.

J Clin Pharmacol. 2003 Jan;43(1):15-22.

PMID:
12520623
34.

Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor.

van Giersbergen PL, Gnerre C, Treiber A, Dingemanse J, Meyer UA.

Eur J Pharmacol. 2002 Aug 23;450(2):115-21.

PMID:
12206849
35.

Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.

Dingemanse J, van Giersbergen PL.

Int J Clin Pharmacol Ther. 2002 Jul;40(7):310-6.

PMID:
12139208
36.

Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist.

van Giersbergen PL, Bodin F, Dingemanse J.

Eur J Clin Pharmacol. 2002 Jul;58(4):243-5. Epub 2002 May 23.

PMID:
12136369
37.

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.

van Giersbergen PL, Halabi A, Dingemanse J.

Br J Clin Pharmacol. 2002 Jun;53(6):589-95.

38.

Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist.

Dingemanse J, Clozel M, van Giersbergen PL.

J Cardiovasc Pharmacol. 2002 Jun;39(6):795-802.

PMID:
12021573
39.
40.

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide.

van Giersbergen PL, Treiber A, Clozel M, Bodin F, Dingemanse J.

Clin Pharmacol Ther. 2002 Apr;71(4):253-62.

PMID:
11956508
41.

Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects.

Dingemanse J, Pedrazzetti E, van Giersbergen PL.

Clin Neuropharmacol. 2001 Mar-Apr;24(2):82-90.

PMID:
11307042
43.

Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist.

Baron BM, Harrison BL, Kehne JH, Schmidt CJ, van Giersbergen PL, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG.

Eur J Pharmacol. 1997 Apr 4;323(2-3):181-92.

PMID:
9128837
44.

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C.

J Pharmacol Exp Ther. 1996 May;277(2):968-81.

PMID:
8627580
45.

In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.

Kudlacz EM, Shatzer SA, Knippenberg RW, Logan DE, Poirot M, van Giersbergen PL, Burkholder TP.

J Pharmacol Exp Ther. 1996 May;277(2):840-51.

PMID:
8627566
46.

Muscarinic toxins from the black mamba Dendroaspis polylepis.

Jolkkonen M, Van Giersbergen PL, Hellman U, Wernstedt C, Oras A, Satyapan N, Adem A, Karlsson E.

Eur J Biochem. 1995 Dec 1;234(2):579-85.

47.

MDL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles.

Kehne JH, Baron BM, Harrison BL, McCloskey TC, Palfreyman MG, Poirot M, Salituro FG, Siegel BW, Slone AL, Van Giersbergen PL, et al.

Eur J Pharmacol. 1995 Sep 15;284(1-2):109-18.

PMID:
8549613
48.

Modulation of agonist binding by guanine nucleotides in CHO cells expressing muscarinic m1-m5 receptors.

van Giersbergen PL, Leppik R.

Naunyn Schmiedebergs Arch Pharmacol. 1995 Aug;352(2):166-72.

PMID:
7477439
49.
50.

Supplemental Content

Loading ...
Support Center